XGN Exagen Inc. stock chart & analysis
Conviction 32HealthcareScan · Fri, Nov 6, 2026Exagen Inc. (XGN) closed at $5.81 (-23.55%) on Nov 6, 2026. Price is below its 50-day and above its 200-day moving average. RSI(14) 30, RS Rating 79, -46.2% from its 52-week high, -4.3% year to date. Sector: Healthcare · Services-Medical Laboratories.
Financials as of Tue, Jun 30, 2026 · quarterly.
XGN technical analysis
Trend
XGN's moving averages are mixed — no clean uptrend or downtrend. It closed 26.6% below the 50-day ($7.93) and 14.1% above the 200-day ($5.10). ADX(14) at 22 points to a moderate trend. It meets 5 of 8 trend-template criteria.
Momentum
RSI(14) is 30, in oversold territory. MACD crossed below its signal line on the latest session. Its RS Rating of 79 puts its weighted 12-month performance ahead of about 79% of the US market.
Volume and volatility
Volume on the latest session ran 1.5× its 20-day average. It trades about $2.8M a day on average. ATR(14) is $0.6446, 11.1% of price — its typical daily range. On-balance volume is trending down. Chaikin Money Flow (-0.14) shows distribution.
Key levels
The chart pattern's support is $7.18 and its resistance $9.06. The 52-week range is $2.59 to $10.83; price is 46.2% below the high and 124.7% above the low. The VWAP anchored at the 52-week high is $5.49, below price.
Performance
XGN returned -32.3% (1 week), -28.8% (1 month), -12.3% (3 months), +97.3% (6 months), -43.7% (1 year), -4.3% (year to date).
About Exagen Inc.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
Services-Medical Laboratories · Listed 2019 · 220 employees
Insider activity
SEC Form 4 transactions in XGN · open-market 2 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Nova Tina Susan Director · Stock Option(right to buy) · 2026-06-09 | Grant | 56.2K | — | 2026-06-09 | 2026-11-02 |
ABALLI JOHN President and CEO · Common Stock · 2026-10-16 | Sell | 34.29K | $270K | 2026-10-16 | 2026-10-19 |
Black Jeffrey G. Chief Financial Officer · Common Stock · 2026-09-01 | Sell | 20.61K | $149K | 2026-09-01 | 2026-09-02 |
Black Jeffrey G. Chief Financial Officer · Common Stock · 2026-09-01 | Grant | 1.57K | $5K | 2026-09-01 | 2026-09-02 |
Robertson Bruce C Director · Stock Option(right to buy) · 2026-06-09 | Grant | 37.5K | — | 2026-06-09 | 2026-08-24 |
Kim Paul Director · Stock Option(right to buy) · 2026-06-09 | Grant | 37.5K | — | 2026-06-09 | 2026-08-19 |
Robertson Bruce C Director · Stock Option(right to buy) · 2026-06-09 | Grant | 37.5K | — | 2026-06-09 | 2026-08-19 |
KAHN SCOTT D Director · Stock Option(right to buy) · 2026-06-09 | Grant | 37.5K | — | 2026-06-09 | 2026-06-22 |
Stokes Frank Director · Stock Option(right to buy) · 2026-06-09 | Grant | 37.5K | — | 2026-06-09 | 2026-06-22 |
McKhann Chas Director · Stock Option(right to buy) · 2026-06-09 | Grant | 37.5K | — | 2026-06-09 | 2026-06-22 |
SEC filings
EDGAR filings in XGN · 3 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.